Please ensure Javascript is enabled for purposes of website accessibility

Gilead to Test an Inhaled Version of Remdesivir

By Keith Speights – Jun 22, 2020 at 11:12AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This version of the investigational antiviral treatment could be administered to COVID-19 patients far more easily, and outside of hospitals.

Gilead Sciences (GILD -2.19%) CEO Daniel O'Day announced on Monday that his company will soon begin a phase 1 clinical trial evaluating an inhaled version of remdesivir as a treatment for patients with COVID-19. The biotech plans to screen healthy volunteers beginning this week with the goal of initiating clinical testing in early-stage COVID-19 patients in August.

Currently, remdesivir is administered to hospitalized COVID-19 patients through intravenous infusion. Gilead thinks that an inhaled version of the drug that patients could take using a nebulizer would be easier to administer outside a hospital setting, and could be given to patients earlier in the course of the illness.

Jigsaw puzzle with "remdesivir drug" printed on one piece and COVID-19 printed on three empty spots

Image source: Getty Images.

The company announced last week that it will soon begin a phase 2/3 clinical study evaluating the IV infusion version of remdesivir in treating pediatric patients with moderate-to-severe COVID-19. Gilead also plans to test the drug using IV infusions in outpatient settings such as infusion centers and nursing homes.

In addition to these clinical trials, results from several studies evaluating remdesivir in combination with other therapies should be on the way over the next few months. One of these studies focuses on a combination of remdesivir and Eli Lilly's Olumiant, while another is testing the combination of remdesivir and Roche's Actemra.

The various studies are necessary because, at this point, the FDA has not approved remdesivir. It did, however, choose to allow doctors to administer the investigational antiviral drug to COVID-19 patients under an emergency use authorization.

Keith Speights owns shares of Gilead Sciences. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
$61.69 (-2.19%) $-1.38

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.